FUGAZZOLA, LAURA
FUGAZZOLA, LAURA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Effect of T3 on Lung Ischemia-Riperfusion Injury in an Evlp Rat Model: Results of Ad Interim Analyses
2023 I. Righi, L. Rosso, M. Cattaneo, C. Lonati, L. Vivona, M. Pinti, M. Battistin, A. Lombardi, V. Selleri, L. Fugazzola, I. Campi, M. Nosotti
Patient-Derived in vitro models for unraveling medullary thyroid cancer microenvironment and therapy resistance
2023 E.S. Grassi, V. Ghiandai, V. Cirello, G. Gazzano, G. Dionigi, L. Persani, L. Fugazzola
Inactivating mutations of TP53 and resistence to tyrosine-kinase inhibitors in patients affected with aggressive thyroid cancer
2023 V. Cirello, C. Colombo, A. Manzo, D. Tosi, U. Gianelli, G. Gazzano, S. Ferrero, L. Persani, L. Fugazzola
Characterization of epcam in thyroid cancer biology by three-dimensional spheroids in vitro model
2023 V. Ghiandai, E.S. Grassi, L. Fugazzola, L. Persani
Targeting the DNA damage response kinase Chk1 in TP53-mutated aggressive thyroid cancers: in vitro studies
2023 A. Manzo, V. Cirello, E.S. Grassi, C. Colombo, L. Fugazzola, L. Persani
Targeting the DNA damage response kinase CHK1 in TP53-mutated thyroid cancer: in vitro studies
2023 A. Manzo, V. Cirello, E.S. Grassi, C. Colombo, L. Fugazzola, L. Persani
Management of hypertension during Lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm
2023 C. Colombo, D. Ceruti, S. DE LEO, G. Bilo, M. Trevisan, N. Giancola, C. Moneta, G. Parati, L. Persani, L. Fugazzola
Fetal cell microchimerism and susceptibility to COVID-19 disease in women
2023 V. Cirello, M. Lugaresi, A. Manzo, E. Balla, G. Fratianni, F. Solari, L. Persani, L. Fugazzola, I. Campi
Clinical outcomes of thermal ablation retreatment of benign thyroid nodules: A multicenter study from the Italian minimally-invasive treatments of the thyroid group
2023 S. Bernardi, V. Rosolen, F. Barbone, S. Borgato, M. Deandrea, P. De Feo, L. Fugazzola, G. Gambelunghe, R. Negro, S. Oleandri, G. Papi, E. Papini, F. Retta, R. Rossetto, D. Sansone, G. Serra, L.M. Sconfienza, L. Solbiati, S. Spiezia, F. Stacul, G. Mauri
Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting
2023 S. De Leo, M. Trevisan, C. Colombo, C. Moneta, N. Giancola, L. Fugazzola
Neoplasie endocrine ereditarie
2022 P. Del Rio, L. Fugazzola, P.G. Calò
Impact of thyroid function screening in a large cohort of patients admitted to an emergency department
2022 I. Campi, G.B. Perego, A. Ravogli, F. Santafede, F. Sileo, A. Dubini, G. Parati, L. Persani, L. Fugazzola
Daily Management of Patients on Multikinase Inhibitors' Treatment
2022 C. Colombo, S. De Leo, M. Trevisan, N. Giancola, A. Scaltrito, L. Fugazzola
FAM83B is involved in thyroid cancer cell differentiation and migration
2022 V. Cirello, E. Grassi, G. Pogliaghi, V. Ghiandai, L. Ermellino, M. Muzza, G. Gazzano, L. Persani, C. Colombo, L. Fugazzola
Tiroide
2022 G. Dionigi, L. Fugazzola, G. Materazzi
Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism
2022 M. Trevisan, C. Colombo, N. Giancola, C. Moneta, G. Dionigi, L. Fugazzola, S. De Leo
The extracellular matrix actively influence thyroid cancer cells sensitivity to TKIS
2022 E.S. Grassi, V. Ghiandai, L. Fugazzola, L. Persani
Three-dimensional spheroids: a new approach for the identification and characterization of novel markers for tumor-initiating cells subpopulations in thyroid cancer
2022 V. Ghiandai, E.S. Grassi, L. Fugazzola, L. Persani
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
2022 I. Campi, G. Vannucchi, I. Muller, E. Lazzaroni, N. Currò, M. Dainese, B. Montacchini, D. Covelli, C. Guastella, L. Pignataro, L. Fugazzola, M. Arosio, M. Salvi
Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
2022 C. Colombo, G. Pogliaghi, D. Tosi, M. Muzza, G. Bulfamante, L. Persani, L. Fugazzola, V. Cirello